mRNA Vaccines as New Immune Treatments for Digestive System Cancers

Messenger RNA vaccines show acceptable safety and clear immunogenicity in early-phase trials for gastrointestinal cancers.

• Personalized mRNA constructs aim to trigger immune responses specifically against tumor cells.
• Early-phase trials have focused on colorectal and pancreatic cancers.
• Challenges such as tumor heterogeneity and immune evasion may affect clinical application.
• Selecting appropriate target antigens is crucial for effective vaccine design.
• Combining mRNA vaccines with immune checkpoint inhibitors is under investigation to enhance treatment responses.
• The long-term benefits of mRNA vaccines in routine clinical use remain to be determined.

Simplified